# US 2016/0250193 A1 · Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250193 A1
- Document ID: US20160250193A1
- Status: Published application
- Kind: A1
- Application number: 15/150,053
- Filed: 2016-05-09
- Published: 2016-09-01
- Earliest claimed: 2010-12-30
- Assignees: Ardea Biosciences, Inc.
- Applicants: Ardea Biosciences, Inc.
- Inventors: Laszlo R. TREIBER; Irina ZAMANSKY; Jean-Luc GIRARDET
- Web page: https://patentgrep.com/patent/US20160250193A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- C07D 249/06: with aryl radicals directly attached to ring atoms
- C07D 249/12: Oxygen or sulfur atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.

## Claims

### Claim 1

A method for treating or preventing gout, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.

### Claim 2 (depends on 1)

The method of claim 1, wherein the crystalline polymorph is further characterized by at least one further peak at 18.21 or 23.08 °2θ±0.1°2θ.

### Claim 3 (depends on 1)

The method of claim 1, wherein the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 5.

### Claim 4 (depends on 1)

The method of claim 1, wherein the crystalline polymorph is prepared by a method comprising the step of crystallizing 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid from a mixture of water and ethyl acetate.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering allopurinol.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering febuxostat.

### Claim 7

A method for treating hyperuricemia, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.

### Claim 8 (depends on 7)

The method of claim 7, wherein the crystalline polymorph is further characterized by at least one further peak at 18.21 or 23.08 °2θ±0.1°2θ.

### Claim 9 (depends on 7)

The method of claim 7, wherein the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 5.

### Claim 10 (depends on 7)

The method of claim 7, wherein the crystalline polymorph is prepared by a method comprising the step of crystallizing 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid from a mixture of water and ethyl acetate.

### Claim 11 (depends on 7)

The method of claim 7, further comprising administering allopurinol.

### Claim 12 (depends on 7)

The method of claim 7, further comprising administering febuxostat.

### Claim 13

A method for treating or preventing a disease caused by elevated uric acid levels, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
characterized by peaks at 10.46, 18.76, and 19.83 °2θ±0.1°2θ.

### Claim 14 (depends on 13)

The method of claim 13, wherein the crystalline polymorph is further characterized by at least one further peak at 18.21 or 23.08 °2θ±0.1°2θ.

### Claim 15 (depends on 13)

The method of claim 13, wherein the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 5.

### Claim 16 (depends on 13)

The method of claim 13, wherein the crystalline polymorph is prepared by a method comprising the step of crystallizing 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid from a mixture of water and ethyl acetate.

### Claim 17 (depends on 13)

The method of claim 13, further comprising administering allopurinol.

### Claim 18 (depends on 13)

The method of claim 13, further comprising administering febuxostat.

### Claim 19 (depends on 13)

The method of claim 13, wherein the disease caused by elevated uric acid levels is gout in a patient with hyperuricemia.

### Claim 20

A method of treating hyperuricemia, treating or preventing gout, or a treating or preventing a disease caused by elevated uric acid levels, comprising administering an effective amount of a crystalline polymorph of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid:
characterized by peaks at 10.32, 18.84 and 20.75 °2θ±0.1°2θ.

### Claim 21 (depends on 20)

The method of claim 20, wherein the crystalline polymorph is further characterized by at least two further peaks at 6.80, 21.54, 24.97, 25.53, 27.28 or 27.60 °2θ±0.1°2θ.

### Claim 22 (depends on 20)

The method of claim 20, wherein the crystalline polymorph exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in FIG. 1.

### Claim 23 (depends on 20)

The method of claim 20, wherein the crystalline polymorphic form of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid is prepared by a method comprising the step of crystallizing 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid from a mixture of water and acetic acid.

### Claim 24 (depends on 20)

The method of claim 20, further comprising administering allopurinol.

### Claim 25 (depends on 20)

The method of claim 20, further comprising administering febuxostat.

### Claim 26 (depends on 20)

The method of claim 20, wherein the disease caused by elevated uric acid levels is gout in a patient with hyperuricemia.
